S. Peters

680 total citations
26 papers, 507 citations indexed

About

S. Peters is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Peters has authored 26 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Hematology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Peters's work include Hematopoietic Stem Cell Transplantation (8 papers), Virus-based gene therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Peters is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), Virus-based gene therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Peters collaborates with scholars based in United States, Germany and Switzerland. S. Peters's co-authors include Hayley S. Ramshaw, Peter J. Quesenberry, Ellen L. W. Kittler, Sudhir Rao, RB Crittenden, Mark S. Dooner, Judith Reilly, Philip Lowry, K. Börner and Thomas Wagner and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Leukemia.

In The Last Decade

S. Peters

23 papers receiving 495 citations

Peers

S. Peters

HEMAT

ONCOL

GENET

PRM

L. Hami United States

R. Nayar Canada

W. Brugger Germany

T.S.K. Wan China

Thomas Möhler Germany

Akihito Fujimi Japan

S. Jani-Sait United States

Maria J. Carnicer Spain

Stéphanie Struski France

Shama L. van Zelderen‐Bhola Netherlands

L. Hami United States

S. Peters

192 ×0.9

HEMAT

118 ×0.7

219 ×1.5

ONCOL

71 ×0.6

GENET

62 ×0.6

PRM

Citations per year, relative to S. Peters S. Peters (= 1×) peers L. Hami

Countries citing papers authored by S. Peters

Since Specialization

Citations

This map shows the geographic impact of S. Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Peters more than expected).

Fields of papers citing papers by S. Peters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Peters. The network helps show where S. Peters may publish in the future.

Co-authorship network of co-authors of S. Peters

This figure shows the co-authorship network connecting the top 25 collaborators of S. Peters. A scholar is included among the top collaborators of S. Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Peters. S. Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Girard, Nicolas, Julia Bar, Daniel C. Christoph, et al.. (2025). 190P: Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R. Journal of Thoracic Oncology. 20(3). S127–S128.

Yamada, Tadaaki, Brian Chan, Wentao Huang, et al.. (2025). MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. Journal of Thoracic Oncology. 20(10). S59–S59.

Valenza, Carmine, Yi Gong, Pietro De Placido, et al.. (2025). Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Annals of Oncology. 36(7). 726–736. 5 indexed citations

Peters, S., David R. Spigel, Myung‐Ju Ahn, et al.. (2021). P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery. Journal of Thoracic Oncology. 16(3). S258–S259. 36 indexed citations

Eberhardt, Wilfried, Benjamin Besse, S. Peters, et al.. (2017). Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie. 71(S 01). S1–S125. 1 indexed citations

Massard, C., Jean‐Charles Soria, Anastasios Stathis, et al.. (2016). A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. European Journal of Cancer. 69. S2–S3. 23 indexed citations

González, Michel, et al.. (2012). [Management pulmonary metastases: when operate?].. PubMed. 8(346). 1326–31. 2 indexed citations

Diehl, Anna Mae, Stephanie Stoelting, Roger Nadrowitz, Thomas Wagner, & S. Peters. (2007). Improved hematopoietic stem cell engraftment following ex vivo expansion of murine marrow cells with SCF and Flt3L. Cytotherapy. 9(6). 532–538. 2 indexed citations

Klink, Thorsten, et al.. (2006). Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. Journal of Cancer Research and Clinical Oncology. 132(10). 643–652. 9 indexed citations

10.

Westermann, Anneke M., G. Wiedemann, Elke Jäger, et al.. (2003). A Systemic Hyperthermia Oncologic Working Group Trial. Oncology. 64(4). 312–321. 23 indexed citations

11.

Bruns, Ingmar, Anne M. Traynor, H. Ian Robins, et al.. (2003). Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer. 39(3). 339–345. 23 indexed citations

12.

Börner, K., et al.. (2000). Metabolism of Ifosfamide to Chloroacetaldehyde Contributes to Antitumor Activity In Vivo. Drug Metabolism and Disposition. 28(5). 573–576. 29 indexed citations

13.

Hänel, Mathias, Nicolaus Kröger, M. Hoffknecht, et al.. (2000). ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas. Annals of Hematology. 79(6). 304–311. 9 indexed citations

14.

Horváth, Viktor J., J. Hartlapp, Susanna Hegewisch‐Becker, et al.. (2000). Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer. Oncology Research and Treatment. 23(4). 341–344. 7 indexed citations

15.

Quesenberry, Peter J., Pamela S. Becker, Susan K. Nilsson, et al.. (1999). Stem cell engraftment and cell cycle phenotype. Leukemia. 13(S1). S92–S93. 5 indexed citations

16.

Peters, S., Ellen L. W. Kittler, Hayley S. Ramshaw, & Peter J. Quesenberry. (1995). Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts.. PubMed. 23(5). 461–9. 152 indexed citations

17.

Quesenberry, PJ, Hayley S. Ramshaw, S. Peters, et al.. (1994). Engraftment of normal murine marrow into nonmyeloablated host mice.. PubMed. 20(2-3). 348–50. 37 indexed citations

18.

Quesenberry, Peter J., RB Crittenden, Philip Lowry, et al.. (1994). In vitro and in vivo studies of stromal niches.. PubMed. 20(1). 97–104; discussion 104. 24 indexed citations

19.

Kalhs, P, et al.. (1993). Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.. PubMed. 12(4). 357–62. 28 indexed citations

20.

Michejda, Maria, et al.. (1990). New Approaches in Bone Marrow Transplantation: The Utilization of Hematopoietic Stem Cells. Fetal Diagnosis and Therapy. 5(1). 40–56. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact